Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States

Expert Rev Pharmacoecon Outcomes Res. 2022 Sep;22(6):1013-1020. doi: 10.1080/14737167.2022.2073223. Epub 2022 May 11.

Abstract

Objective: This study investigated the direct medical and indirect (i.e. absenteeism) costs among working adults diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States.

Methods: This study utilized 2017-2018 Medical Expenditure Panel Survey data. Attribution and regression-based incremental cost approaches were utilized to estimate direct medical costs, i.e. prescription drug costs and total costs. The regression-based approach was utilized to estimate absenteeism cost.

Results: The study sample consisted of 32,222 observations (weighted: 187,207,896). Of these, 459 (weighted: 3,175,033) had ADHD. The mean annual per person ADHD-attributable prescription drug cost was 2018 US $1,248 (standard error (SE): 97) and the ADHD-attributable total cost was $2,031 (SE: 371). This contributed to a mean overall annual spending of $3.96 (SE: 0.42) billion on ADHD-attributable prescription drugs and $6.45 (SE: 1.26) billion on ADHD-attributable total direct medical costs among adult ADHD patients. Based on the regression-based approach, the mean annual incremental cost for ADHD was $1,641 (SE: 164) and $4,328 (SE: 862) per person for prescription medication costs and total costs, respectively. The mean indirect cost of ADHD was estimated at $512 (SE: 91) per year, per person among working adults with ADHD in the United States.

Conclusions: There is a significant direct and indirect economic burden on working adults with ADHD.

Expert opinion: There is a significant economic burden of ADHD in terms of direct medical (including out-of-pocket) cost as well as indirect absenteeism cost. The per person annual costs estimated using a regression approach were approximately twice as much as the costs using the sum disease-specific approach, suggesting a potential role for 'spillover' costs among working adults with ADHD. Prescription drug costs were top-ranked contributors to the direct medical costs. As a group, working adults with ADHD are relatively understudied and more research is needed to better understand the burden of ADHD in this group.

Keywords: ADHD; Attention-Deficit/Hyperactivity Disorder; Medical Expenditure Panel Survey; adult ADHD; direct medical cost; indirect cost; productivity cost.

MeSH terms

  • Absenteeism
  • Adult
  • Attention Deficit Disorder with Hyperactivity*
  • Cost of Illness
  • Drug Costs
  • Health Care Costs
  • Humans
  • Prescription Drugs*
  • United States

Substances

  • Prescription Drugs